PARP1 and metabolic dysfunction-associated steatotic liver disease: However, a conflicting report concludes robust increases in PARP activity in livers of obese mice and nonalcoholic fatty liver disease (NAFLD) patients and that inhibition of PARP1 activation alleviates lipid accumulation and inflammation in fatty liver (38).